Earnings
Under the terms of the agreement, Bristol Myers Squibb will take over complete responsibility for the development and commercialization of AGEN1777 and any related products globally.
Empaveli (pegcetacoplan) is the first and only targeted C3 therapy for the treatment of adults with PNH, the Waltham, Mass.-based company said in its announcement.
Humanigen reported it had held a meeting with the FDA to discuss plans for filing an EUA for its lenzilumab for hospitalized, hypoxic COVID-19 patients by the end of May.
SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.
The company has raised approximately $1.3 billion in external financing over the past three years, including $310 million in 2020.
Two new venture capital funds, Droia Ventures and Perceptive Advisors closed on new funds to invest in early-stage life science companies.
2021 is shaping up to be another banner year for biotech companies as they advance the next gen technologies and therapeutics for the health of all. Here’s a few raking in cash for their programs today.
Shanghai-based Alebund Pharmaceuticals has raised $60 million in a new Series B financing round that will be harnessed to further drive the company’s focus on renal disease.
London-based venture capital fund Abingworth closed on a new Clinical Co-Development Fund now at $582 million. The fund’s original target was just at $350 million.
Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.
PRESS RELEASES